Literature DB >> 22744429

Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function.

E Z H Sung1, R P Arasaradnam, E M Jarvie, S James, S J Goodyear, R A Borman, D Snead, G J Sanger, C U Nwokolo.   

Abstract

Delayed gastric emptying symptoms are often reported after chemotherapy. This study aims to characterise the effects of chemotherapy on gastric neuro-muscular function. Patients undergoing elective surgery for oesophago-gastric cancer were recruited. Acetylcholinesterase, nNOS, ghrelin receptor and motilin expressions were studied in gastric sections from patients receiving no chemotherapy (n = 3) or oesophageal (n = 2) or gastric (n = 2) chemotherapy. A scoring system quantified staining intensity (0-3; no staining to strong). Stomach sections were separately suspended in tissue baths for electrical field stimulation (EFS) and exposure to erythromycin or carbachol; three patients had no chemotherapy; four completed cisplatin-based chemotherapy within 6 weeks prior to surgery. AChE expression was markedly decreased after chemotherapy (scores 2.3 ± 0.7, 0.5 ± 0.2 and 0 ± 0 in non-chemotherapy, oesophageal- and gastric-chemotherapy groups (p < 0.03 each) respectively. Ghrelin receptor and motilin expression tended to increase (ghrelin: 0.7 ± 0.4 vs 2.0 ± 0.4 and 1.2 ± 0.2 respectively; p = 0.04 and p = 0.2; motilin: 0.7 ± 0.5 vs 2.2 ± 0.5 and 2.0 ± 0.7; p = 0.06 and p = 0.16). Maximal contraction to carbachol was 3.7 ± 0.7 g and 1.9 ± 0.8 g (longitudinal muscle) and 3.4 ± 0.4 g and 1.6 ± 0.6 (circular) in non-chemotherapy and chemotherapy tissues respectively (p < 0.05 each). There were loss of AChE and reduction in contractility to carbachol. The tendency for ghrelin receptors to increase suggests an attempt to upregulate compensating systems. Our study offers a mechanism by which chemotherapy markedly alters neuro-muscular gastric function.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22744429     DOI: 10.1007/s11033-012-1866-7

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  13 in total

1.  Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

2.  The role of electrogastrography and gastrointestinal hormones in chemotherapy-related dyspeptic symptoms.

Authors:  Giuseppe Riezzo; Caterina Clemente; Silvana Leo; Francesco Russo
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

3.  Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents.

Authors:  Y-L Liu; N M Malik; G J Sanger; P L R Andrews
Journal:  Cancer Chemother Pharmacol       Date:  2006-01-25       Impact factor: 3.333

4.  Assessment of the intestinal permeability after a gastrectomy and the oral administration of anticancer drugs in rats: nitric oxide release in response to gut injury.

Authors:  Shunichi Nagahama; Daisuke Korenaga; Masayuki Honda; Sadaaki Inutsuka; Keizo Sugimachi
Journal:  Surgery       Date:  2002-01       Impact factor: 3.982

5.  Effects of cisplatin and taxol on inducible nitric oxide synthase, gastrin and somatostatin in gastrointestinal toxicity.

Authors:  Y Wang; S K Aggarwal
Journal:  Anticancer Drugs       Date:  1997-10       Impact factor: 2.248

6.  Cisplatin-induced inhibition of the calcium-calmodulin complex, neuronal nitric oxide synthase activation and their role in stomach distention.

Authors:  R K Jarve; S K Aggarwal
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

7.  Effect of chemotherapy on circulating gastrointestinal hormone levels in ovarian cancer patients: relationship to nausea and vomiting.

Authors:  Timo J Hursti; Sussanne Börjeson; Per M Hellström; Elisabeth Avall-Lundqvist; Solveig Stock; Gunnar Steineck; Curt Peterson
Journal:  Scand J Gastroenterol       Date:  2005-06       Impact factor: 2.423

8.  Adaptive upregulation of gastric and hypothalamic ghrelin receptors and increased plasma ghrelin in a model of cancer chemotherapy-induced dyspepsia.

Authors:  N M Malik; G B T Moore; R Kaur; Y-L Liu; S L Wood; R W Morrow; G J Sanger; P L R Andrews
Journal:  Regul Pept       Date:  2008-03-25

Review 9.  Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ.

Authors:  Akio Inui; Akihiro Asakawa; Cyril Y Bowers; Giovanni Mantovani; Alessandro Laviano; Michael M Meguid; Mineko Fujimiya
Journal:  FASEB J       Date:  2004-03       Impact factor: 5.191

Review 10.  Cancer and chemotherapy-related upper gastrointestinal symptoms: the role of abnormal gastric motor function and its evaluation in cancer patients.

Authors:  Kristine Nelson; Declan Walsh; Finbar Sheehan
Journal:  Support Care Cancer       Date:  2002-07-03       Impact factor: 3.603

View more
  2 in total

1.  Gender-differences of in vitro colonic motility after chemo- and radiotherapy in humans.

Authors:  Maria Antonietta Maselli; Antonia Ignazzi; Francesco Pezzolla; Annunziata Scirocco; Dionigi Lorusso; Fabrizio De Ponti; Carola Severi
Journal:  BMC Pharmacol Toxicol       Date:  2018-08-03       Impact factor: 2.483

2.  Short-term outcome of Ivor Lewis esophagectomy following neoadjuvant chemoradiation versus perioperative chemotherapy in patients with locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: a propensity score-matched analysis.

Authors:  Patrick Sven Plum; Alexander Damanakis; Lisa Buschmann; Angela Ernst; Rabi Raj Datta; Lars Mortimer Schiffmann; Thomas Zander; Hans Fuchs; Seung-Hun Chon; Hakan Alakus; Wolfgang Schröder; Arnulf Heinrich Hölscher; Christiane Josephine Bruns; Marc Bludau
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-05       Impact factor: 4.322

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.